Every year 65,000 people in England, Wales and Northern Ireland break their hip and undergo surgery. This is a devastating injury for these typically elderly, frail and anaemic patients. As a result of the break and the surgery, 30% of patients require a transfusion of someone else’s donated blood. This can lead to complications, increase the risk of infections (e.g. pneumonia or a wound infection) and increases the length of the hospital stay.
Fractures of the proximal femur (hip fractures) are one of the greatest challenges facing the medical community. In 1990, a global incidence of 1.31 million was reported and was associated with 740,000 deaths. Hip fractures constitute a heavy socioeconomic burden worldwide. The cost of this clinical problem is estimated at 1.75 million disability adjusted life years lost, 1.4% of the total healthcare burden in established market economies.
The European Health Data and Evidence Network (EHDEN), an IMI 2 consortium with 23 partners, is a multi-stakeholder, interdisciplinary, open-science collaborative maximising the value of health data through large-scale analytics.
The EHDEN public private project was set up under the framework of IMI2, with twenty-two partners, including academia, SMEs, patient associations, regulatory authorities and pharmaceutical companies, led by Erasmus Medical Centre, The Netherlands, and Janssen Pharmaceutica N.V., Belgium.